- Top of page
- Patients and methods
Summary. Background: A reduced sensitivity for activated protein C (APC) is associated with an increased risk of venous thrombosis even in the absence of the factor (F)V Leiden mutation. This risk has been demonstrated with two APC sensitivity tests, which quantify the effects of APC on the activated partial thromboplastin time (APTT) and the endogenous thrombin potential (ETP), respectively. Objectives: We examined determinants of both APC sensitivity tests in the control group of the Leiden Thrombophilia Study (LETS). Methods: Multiple linear regression analysis was performed with normalized APC-SRAPTT or APC-SRETP as dependent variable and putative determinants [levels of FII, FV, FVII, FVIII, FIX, FX, FXI, FXII, FXIII A subunit, FXIII B subunit, protein S total, protein S free, protein C, tissue factor pathway inhibitor (TFPI) total, TFPI free, antithrombin and fibrinogen] as independent variables. Results and conclusions: The major determinant of the APTT-based test was FVIII level, followed by FII level. The ETP-based test was influenced most by free protein S and free TFPI levels. In both tests FXa formation plays a major role, as the effect of FVIII and TFPI on the tests seems to be executed via FXa. The ETP-based test was also strongly influenced by oral contraceptive use, even when we adjusted for all the clotting factors listed above. This means that the effect of oral contraceptives on the ETP-based test is not fully explained by the changes of coagulation factor levels investigated in this study, and that the molecular basis of acquired APC resistance during use of oral contraceptives remains to be established.
- Top of page
- Patients and methods
Activated protein C (APC), in combination with its cofactor protein S, acts as an anticoagulant by inactivating the activated cofactors factor (F)Va and FVIIIa by specific peptide bond cleavages. Factor V acts together with protein S as a cofactor of APC in the inactivation of activated FVIII. In 1993, Dahlbäck et al. reported a new mechanism for thrombophilia, characterized by a poor anticoagulant response of plasma to APC . Most cases of this so-called APC resistance are caused by a mutation in one of the APC cleavage sites (Arg506) of FV (FV Leiden) . This mutation is a common risk factor for venous thrombosis.
Several methods for the detection of APC resistance have been developed. The original test of Dahlbäck et al. evaluates the increase of the activated partial thromboplastin time (APTT) after addition of a fixed amount of APC to plasma . Reduced prolongation of the APTT indicates resistance to the anticoagulant action of APC. The sensitivity and specificity for the FV Leiden mutation is dependent on the APTT reagent used . A disadvantage of the APTT-based test is that it cannot be used in patients using oral anticoagulants or with lupus anticoagulants, because of their prolonged baseline APTT.
Rosing and co-workers developed an APC sensitivity test which is based on quantification of the effect of APC on the endogenous thrombin potential (ETP), i.e. on the time integral of thrombin generated in plasma in which coagulation is initiated via the extrinsic pathway [4,5].
In addition to the above-mentioned APTT- and ETP-based tests several other APC sensitivity tests were developed based on the prolongation by APC of the prothrombin time, the FXa clotting time, the Russell Viper venom time, or the textarin time. Also modified tests, in which patient plasma is diluted in FV-deficient plasma, have been developed which have a high sensitivity and specificity for the FV Leiden mutation also in patients using oral anticoagulants and in patients with lupus anticoagulants. A disadvantage of these latter tests is that they cannot detect a reduced sensitivity for APC in the absence of FV Leiden.
It has been demonstrated with both the APTT- and the ETP-based APC sensitivity test that a reduced sensitivity for APC not because of FV Leiden also increases the risk of venous thrombosis [6–8]. Causes of such a reduced response to APC are for instance pregnancy, oral contraceptive use, hormone replacement therapy, lupus anticoagulants, and high FVIII levels. The detection of these acquired APC-resistant phenotypes depends on the test that is used, e.g. in the ETP-based test plasma of women using oral contraceptives appeared to be considerably APC-resistant , while in the APTT-based test FVIII levels seemed to be a major determinant [6,10]. So, the APTT- and the ETP-based APC sensitivity tests are both global tests that can predict thrombosis risk [6–8], but they seem to have different determinants. The aim of this study was to examine extensively the determinants of the APTT- and ETP-based APC sensitivity tests. Knowledge of the main determinants may help us understand the mechanisms leading to APC resistance. For our investigation we used a large group of individuals without a history of venous thrombosis (the control group of the Leiden Thrombophilia Study, LETS).
- Top of page
- Patients and methods
In Fig. 1 the normalized APC-SRETP is plotted against the normalized APC-SRAPTT. Because APC inhibits thrombin formation and prolongs the APTT, plasmas with a reduced sensitivity for APC will give a decrease of the normalized APC-SR in the APTT-based test and an increase in the ETP-based test. The two normalized ratios were associated, but there was considerable variation (regression coefficient β = −4.9; 95% CI: −6.1 to −3.6). In Table 1, the mean normalized APC ratios for the two tests are shown for the whole population and stratified for sex and oral contraceptive use.
Figure 1. Normalized activated protein C (APC)-SRETP vs. normalized APC-SRAPTT. Regression line: n-APC-SRETP = 7.3 − 4.9 × n-APC-SRAPTT.
Download figure to PowerPoint
Table 1. Mean APC sensitivity in healthy individuals
| ||n||n-APC-SRAPTT (95% CI)||n-APC-SRETP (95% CI)|
|All||407||1.02 (1.01–1.03)||2.33 (2.18–2.48)|
| Men||166||1.05 (1.04–1.07)||1.38 (1.27–1.49)|
| Women||241||0.99 (0.98–1.00)||2.99 (2.78–3.19)|
|Use of oral contraceptives*|
| Yes||53||0.94 (0.92–0.96)||4.88 (4.44–5.32)|
| No||172||1.00 (0.99–1.02)||2.43 (2.26–2.61)|
Results of the two APC sensitivity tests in the complete population-based case–control study have been described elsewhere [6,8]. The main purpose of the present study was to assess determinants of both tests by a multiple linear regression model. In this model (model 1, Table 2) the main determinant of the APTT-based test appeared to be FVIII level (standardized regression coefficient β = −0.55) followed by FII (prothrombin) level (β = −0.25). The ETP-based test was influenced most by free TFPI (β = −0.39) and free protein S levels (β = −0.33). Addition of sex, age, and oral contraceptive use to the model (model 2, Table 3), only resulted in marginal changes in the effect of the coagulation factors on the APTT-based test. The regression coefficients for the two most important determinants, FVIII (β = −0.52) and FII level (β = −0.23), hardly changed with this adjustment. However, adjustment for sex, age, and oral contraceptive use reduced the effects of the major determinants of the ETP-based test, namely free TFPI level (β = −0.25) and free protein S level (β = −0.26). Oral contraceptive use appeared to be a strong determinant of the ETP-based test. Even after adjustment for many coagulation factors (model 2), oral contraceptive use led to an average increase of the normalized APC-SRETP with 0.78 SD. The influence of oral contraceptive use on the APTT-based test was less (β = −0.21). In both tests women had a reduced sensitivity for APC compared with men. Sex had a larger effect on the ETP-based test (β = 0.44) than on the APTT-based test (β = −0.24). There was no influence of age (SD: 13.3) on the ETP-based test and only a small effect on the APTT-based test (β = −0.13).
Table 2. Mean change in normalized APC-SR (SD*) with 1 SD increase in coagulation factor (model 1)
| ||SD||β (95% CI)|
|APTT-based test||ETP-based test|
|Factor II||15.0||−0.25 (−0.33 to −0.18)||0.15 (0.07–0.23)|
|Factor V||31.8||0.15 (0.07–0.22)||−0.14 (−0.21 to −0.06)|
|Factor VII||21.7||−0.09 (−0.17 to −0.02)||0.10 (0.03–0.18)|
|Factor VIII||32.5||−0.55 (−0.62 to −0.48)||0.05 (−0.02 to 0.12)|
|Factor IX||19.8||−0.12 (−0.21 to −0.04)||0.20 (0.11–0.28)|
|Factor X||16.8||−0.12 (0.21 to −0.04)||0.11 (0.02–0.19)|
|Factor XI||19.5||−0.07 (−0.14 to −0.001)||0.06 (−0.01 to 0.13)|
|Factor XII||28.4||0.08 (0.01–0.15)||0.02 (−0.06 to 0.09)|
|Factor XIII A||23.7||0.03 (−0.07 to 0.13)||0 (−0.10 to 0.10)|
|Factor XIII B||18.5||0.01 (−0.10 to 0.12)||0.02 (−0.09 to 0.13)|
|Protein S total||19.7||0.01 (−0.08 to 0.11)||−0.18 (−0.27 to −0.09)|
|Protein S free||20.5||0.10 (0.01–0.19)||−0.33 (−0.42 to −0.23)|
|Protein C||18.1||−0.15 (−0.22 to −0.07)||0.02 (−0.06 to 0.10)|
|TFPI total||15.1||−0.02 (−0.11 to 0.07)||−0.03 (−0.12 to 0.06)|
|TFPI free||4.81||0.13 (0.03–0.22)||−0.39 (−0.49 to −0.30)|
|Antithrombin||10.5||0.02 (−0.05 to 0.09)||−0.07 (−0.15 to −0.01)|
|Fibrinogen||0.65||0.07 (−0.01 to 0.16)||−0.03 (−0.11 to 0.06)|
Table 3. Multiple linear regression including age, sex, and oral contraceptive use (model 2)
| ||β (95% CI)|
|APTT-based test||ETP-based test|
|Factor II||−0.23 (−0.31 to −0.15)||0.07 (−0.001 to 0.15)|
|Factor V||0.13 (0.06–0.21)||−0.11 (−0.17 to −0.04)|
|Factor VII||−0.07 (−0.15 to 0.01)||0.07 (0.001–0.14)|
|Factor VIII||−0.52 (−0.60 to −0.45)||0.04 (−0.03 to 0.11)|
|Factor IX||−0.11 (−0.20 to −0.03)||0.16 (0.08–0.24)|
|Factor X||−0.15 (−0.24 to −0.05)||0.03 (−0.05 to 0.12)|
|Factor XI||−0.04 (−0.12 to 0.03)||0.03 (−0.03 to 0.10)|
|Factor XII||0.09 (0.02–0.17)||−0.03 (−0.10 to 0.04)|
|Factor XIII A||0.05 (−0.05 to 0.16)||−0.02 (−0.12 to 0.07)|
|Factor XIII B||−0.01 (−0.12 to 0.11)||0.06 (−0.05 to 0.16)|
|Protein S total||0.01 (−0.09 to 0.11)||−0.09 (−0.18 to 0.01)|
|Protein S free||0.09 (−0.01 to 0.18)||−0.26 (−0.35 to −0.17)|
|Protein C||−0.13 (−0.21 to −0.05)||−0.01 (−0.08 to 0.07)|
|TFPI total||−0.02 (−0.11 to 0.07)||0.02 (−0.06 to 0.11)|
|TFPI free||0.09 (−0.01 to 0.19)||−0.25 (−0.34 to −0.15)|
|Antithrombin||−0.01 (−0.09 to 0.06)||−0.05 (−0.12 to 0.02)|
|Fibrinogen||0.10 (0.01–0.18)||−0.05 (−0.12 to 0.03)|
|Age||−0.13 (−0.21 to −0.04)||−0.04 (−0.12 to 0.04)|
|Sex*||−0.24 (−0.39 to −0.08)||0.44 (0.29–0.59)|
|Oral contraceptive use†||−0.21 (−0.51 to 0.10)||0.78 (0.50–1.07)|
Because an APC sensitivity test is a global test, it is not surprising that the test is influenced by many of the examined variables. We examined more closely the coagulation parameters with the strongest effect on the two tests, i.e. levels of FII, FVIII, free protein S, and free TFPI. These four variables were stratified into quartiles and for each quartile the mean normalized APC-SRAPTT and the mean normalized APC-SRETP were calculated (Table 4). When FVIII levels increase, the mean normalized APC-SRAPTT decreases, while such a clear trend was not observed for the normalized APC-SRETP. A similar trend, but weaker, was seen for FII levels. In contrast, free protein S levels and free TFPI levels show an association with the normalized APC-SRETP and not with the normalized APC-SRAPTT.
Table 4. Mean normalized APC-SRAPTT and mean normalized APC-SRETP for quartiles of factor II, factor VIII, protein S free, and TFPI free
| ||Number of subjects||Mean n-APC-SRAPTT (95% CI)||Mean n-APC-SRETP (95% CI)|
|Factor II (U dL−1)|
| <94||99||1.07 (1.05–1.09)||2.21 (1.94–2.47)|
| 94–103||106||1.03 (1.01–1.06)||2.21 (1.93–2.49)|
| 103–113||97||1.01 (0.99–1.04)||2.57 (2.17–2.97)|
| >113||105||0.96 (0.94–0.97)||2.36 (2.10–2.62)|
|Factor VIII (U dL−1)|
| <99||101||1.11 (1.09–1.14)||2.11 (1.89–2.34)|
| 99–119||105||1.03 (1.02–1.05)||2.39 (2.06–2.73)|
| 119–143||99||0.99 (0.98–1.01)||2.32 (2.01–2.63)|
| >143||102||0.93 (0.92–0.94)||2.50 (2.18–2.83)|
|Protein S free (U dL−1)|
| <83||99||1.02 (1.00–1.05)||3.34 (2.98–3.71)|
| 83–96||104||1.03 (1.01–1.06)||2.54 (2.25–2.83)|
| 96–111||99||1.02 (1.00–1.04)||1.82 (1.61–2.03)|
| >111||105||1.00 (0.98–1.02)||1.66 (1.45–1.87)|
|TFPI free (ng mL−1)|
| <9.5||101||0.99 (0.97–1.01)||3.96 (3.63–4.30)|
| 9.5–12.5||102||1.05 (1.02–1.07)||2.24 (2.02–2.46)|
| 12.5–15.3||102||1.02 (1.00–1.03)||1.84 (1.67–2.02)|
| >15.3||102||1.02 (1.00–1.04)||1.31 (1.15–1.46)|
- Top of page
- Patients and methods
A reduced sensitivity for APC, as measured with the APTT- or the ETP-based APC sensitivity test, is associated with an increased risk of venous thrombosis both in the absence and presence of FV Leiden [6,8,11]. In this study we found that many coagulation factors have an effect on these global tests, with the APTT-based APC sensitivity test mainly influenced by FVIII levels and the ETP-based test by free TFPI and free protein S levels. The latter test was also highly dependent on oral contraceptive use.
We found that increased FII (prothrombin) levels reduced the sensitivity for APC in the APTT-based test. In a model system containing purified proteins it has been demonstrated before that prothrombin inhibits the ability of APC to inactivate FVa . Furthermore, it has been shown in a group of 285 normal subjects that hyperprothrombinemia may lead to APC resistance . By diluting normal plasma in FII-deficient plasma de Ronde and Bertina previously demonstrated that a reduction in prothrombin level leads to an increased sensitivity for APC in the APTT-based test . Castaman et al. obtained the same results by adding purified prothrombin to normal plasma . In the same study, the response to APC was assessed in families with the prothrombin 20210A variation, which is associated with increased prothrombin levels . A reduced sensitivity for APC was found in 20210A heterozygotes compared with wild-type carriers . All these studies suggest that FII levels influence the APTT-based APC sensitivity test. Our results show, however, that this effect is moderate and weaker than the observed effect of FVIII levels on the APTT-based test.
A reduction in sensitivity for APC at increased FVIII levels was demonstrated earlier both with our local APTT-based APC sensitivity test (with Cephotest® as activator)  and with a commercial APTT-based APC sensitivity test (Coatest® APCTM Resistance, Chromogenix, Milan, Italy) [10,28]. No significant effect of FVIII was observed in the ETP-based test, although the data in Table 4 suggest that FVIII levels may have a minor effect on the normalized APC-SRETP. The insensitivity of the ETP-based test for FVIII levels is probably due to the high tissue factor concentration present in the ETP test used in this study. Lowering the tissue factor concentration probably will make thrombin generation more dependent on the concentration of the components of the tenase complex (FIX, FVIII) . It will be of interest to see whether reduction of the tissue factor concentration will result in a higher sensitivity of the ETP-based test for FVIII levels.
The fact that the APTT-based test is greatly influenced by FVIII levels suggests that FXa formation plays an important role in this test. An increase in FVIII level will lead to increased activation of FX. Increased FXa formation can result in a reduced sensitivity for APC, as it was shown that FXa protects FVa from inactivation by APC [30–34] by selectively blocking cleavage at Arg506 , which results in slow inactivation of FVa via APC-mediated cleavage at Arg306 [36–38]. FXa formation also seems to be important in the ETP-based test. Namely, in agreement with previous findings , we found that the latter test is influenced by free TFPI levels, with a reduction in free TFPI level leading to a reduced sensitivity for APC. TFPI is an inhibitor that regulates the extrinsic (tissue factor-induced) coagulation pathway. TFPI inhibits FXa and the FXa/TFPI complex is a potent inhibitor of the tissue factor/FVIIa complex (for a review see Ref. ). When free TFPI levels are reduced this will lead to an initial increase in FXa formation, which, by the above-mentioned mechanism (i.e. protection at Arg506) , might result in a reduced sensitivity for APC. Curvers et al.  demonstrated that the efficacy by which APC inhibits thrombin formation in the ETP-based test is decreased at high tissue factor concentrations . In view of this observation it is not surprising that the ETP-based test is influenced by free TFPI levels.
We confirmed that a reduction in free protein S level leads to a reduced sensitivity in the ETP-based APC sensitivity test [39,41,42]. In contrast, de Ronde and Bertina showed before by diluting normal plasma in protein S-deficient plasma that the APTT-based test is only affected by very low protein S levels (<20 U dL−1) . Protein S is a cofactor of APC, which specifically accelerates APC-mediated cleavage at Arg306 of FVa . A reduced protein S level will lead to a reduced cleavage of FVa at Arg306 by APC, resulting in a delayed FVa inactivation and in increased thrombin formation. The fact that the ETP-based test is affected by protein S level whereas the APTT-based test is not, might suggest that the Arg306 cleavage is more important in the ETP-based test than in the APTT-based test.
The APTT-based APC sensitivity test was only moderately influenced by sex and oral contraceptive use, while the ETP-based test was strongly affected by these variables. In the latter test women have a reduced response to APC compared with men and oral contraceptive users have the lowest response. This effect cannot be explained by a reduction of protein S levels in oral contraceptive users, because in our study population free protein S levels were not materially different in women using oral contraceptives compared with non-users [43,44]. Furthermore, addition of oral contraceptive use to the multiple regression model (model 2) only slightly reduced the effect of free protein S on the test. Part of the effect of oral contraceptives on the APC response may be executed via TFPI. It has been reported that women taking oral contraceptives have reduced TFPI levels  and we showed here that adjustment for oral contraceptive use reduced the influence of free TFPI level on the test. Initiation of coagulation occurs in the case of the APTT via the intrinsic pathway and in the case of the ETP via the extrinsic pathway (tissue factor/FVIIa). This indicates that the basis of the impaired APC response in women using oral contraceptives may be sought in the activity or regulation of the extrinsic pathway. Because oral contraceptive use affects the concentrations of many proteins involved in blood coagulation  a combination of these effects will most likely lead to a reduced sensitivity for APC. However, in our analysis a strong effect of oral contraceptive use on the ETP-based test persisted (β = 0.78) when several coagulation factors were taken into account (model 2). This means that the effect of oral contraceptives on the ETP-based test is mediated by variables (e.g. coagulation factors or other plasma components) that were not included in our analysis. Also the differences in APC sensitivity between men and women in both the ETP-based and the APTT-based test are not fully explained by the other variables in the model, because an effect of sex (β = −0.24 for the APTT-based test and β = 0.44 for the ETP-based test) on the APC sensitivity still exists (model 2).
We observed a moderate correlation between the APC sensitivity measured with the APTT-based test and the sensitivity measured with the ETP-based test (see Fig. 1). It is therefore good to realize that a person who is typed ‘APC-resistant’ in the ETP-based test will not by definition be APC-resistant in the APTT-based test. The two global tests evaluate APC resistance via different pathways. It will be of interest to investigate whether it is possible to design a test, which is sensitive for FVIII and prothrombin as well as free protein S, and free TFPI.